NICE
ABPI president: NICE needs political reform
June 17, 2014Business Services, Medical Communications, Research and Development ABPI, NHS, NICE, Pfizer, QALY, emms, jonathan, vba
NICE needs to be reformed with its QALY formula heavily revised if it is to meet the challenges of 21st …
NICE rejection looms for Sovaldi
June 16, 2014Sales and Marketing Gilead, NHS, NICE, SMC, hep C, sofosbuvir, sovaldi
In a draft recommendation published today NICE is asking Gilead for more information on its new hepatitis C pill Sovaldi …
NICE recommends Yervoy
June 13, 2014Sales and Marketing BMS, Cancer, Dillon, NHS, NICE, Yervoy, melanoma
Bristol-Myers Squibb has received a lift from the UK’s drugs watchdog, which has recommended its vaccine Yervoy as a first-line …
Researchers question ‘bias’ NICE on statins
June 11, 2014Sales and Marketing Drug pricing, Haslam, NHS, NICE, statins
Doctors are warning that NICE’s desire to increase prescriptions of statins in England is based on pharma-funded research that ignores …
David Haslam: NICE, drug pricing and ethics
June 2, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chairman, Dillon, NHS, NICE, adams, has lam
Since 2010, I have spent a great deal of time of writing about NICE, covering nearly all of all its …
NICE: no early Zytiga use
May 14, 2014Sales and Marketing Cancer, Janssen, NHS, NICE, Zytiga, johnson, prostate
Janssen has criticised NICE’s decision not to recommend Zytiga on the NHS at an earlier stage in the prostate cancer …
NICE recommends Xtandi
May 9, 2014Sales and Marketing Astellas, NICE, Xtandi, abiraterone, prostate
NICE has reiterated that Astellas Pharma’s Xtandi should be used to treat NHS prostate cancer patients – but has removed …
US cancer docs warn of rising drug prices
May 7, 2014Research and Development, Sales and Marketing ASCO, Cancer, NICE, Obama, US, United States, republicans
American cancer doctors are warning that the rising price of oncology medicines is making it unaffordable for the country’s healthcare …
NICE chair: pharma must show how it prices drugs
April 28, 2014Research and Development, Sales and Marketing Goldacre, Haslam, NICE, VBP, all trials, pars
The pharmaceutical industry must be willing to show the public how it prices its drugs – or face losing its …
NICE rejects Kadcyla
April 23, 2014Sales and Marketing CDF, Cancer, Genentech, Kadcyla, NHS, NICE, Roche
NICE has delivered a severe blow to Roche by rejecting its breast cancer ‘smart bomb’ Kadcyla for NHS use in …
NHS needs to understand drug costs better, says ABPI
April 10, 2014Medical Communications, Research and Development, Sales and Marketing ABPI, AGNSS, Deepak Khanna, NICE, Stephen Whitehead, Tarceva, soliris
The UK healthcare system is at risk of failing to adopt new, personalised medicines and must be willing to pay …
NICE U-turn on Roche cancer drug
April 4, 2014Medical Communications, Sales and Marketing NICE, Roche, Tarceva, U-turn
Roche’s lung cancer drug Tarceva has been given a reprieve to treat relapsed lung cancer patients in the NHS after …
Stelara hit by final NICE rejection
March 28, 2014Sales and Marketing Janssen, NICE, UK, arthritis, psoriatic, stelar
In final draft guidance released today NICE says it cannot recommend Janssen’s psoriatic arthritis drug Stelara. Specifically, the pricing watchdog …
NICE launches VBA consultation
March 27, 2014Sales and Marketing Dillon, England, NHS, NICE, VBP, catchpole, pars, vba
NICE has today launched its consultation into how value-based assessment of drugs will work in practice, which will run for …
Pfizer’s Xalkori impresses in new setting
March 26, 2014Research and Development, Sales and Marketing NHS, NICE, NSCLC, Pfizer, Xalkori, lung cancer
Pfizer’s lung cancer treatment Xalkori has proven better at treating patients in a first-line setting when compared to chemotherapy. This …
Latest content
FibroFind appoints Lee Borthwick as CEO
